Anonymous Client J — Top-20 pharma company ($4.2B revenue, established cardiovascular portfolio)
The company's cardiovascular portfolio included 3 marketed products and 2 late-stage pipeline assets. Developed market revenue was declining at 4% annually due to loss of exclusivity on 2 products. The board had set a target of generating 25% of revenue from emerging markets within 5 years (up from 8% currently). However, the company had no dedicated emerging markets team, no local market intelligence, and 2 failed market entry attempts in China and Brazil.
A top-20 pharma company with an established cardiovascular portfolio generating $1.8B in revenue faced stagnating growth in developed markets due to generic erosion and payer pressure. They needed an emerging markets expansion strategy across 8 countries in Asia-Pacific and Latin America, but lacked local market intelligence, regulatory pathway knowledge, and partnership frameworks. Previous attempts at emerging market entry had failed due to poor partner selection and inadequate pricing strategies.
We conducted a comprehensive market attractiveness analysis across 8 emerging markets, evaluating patient populations, regulatory pathways, pricing environments, healthcare infrastructure, and local partnership opportunities. Our team combined quantitative market sizing with qualitative assessment of regulatory complexity, partnership landscape, and competitive dynamics. We delivered a phased market entry roadmap with partner identification, pricing strategy, and investment projections.
Market attractiveness scoring: Evaluated 8 emerging markets across 10 dimensions including patient population, market growth, regulatory complexity, pricing environment, healthcare infrastructure, IP protection, competition, partnership availability, political stability, and revenue potential
Patient population analysis: Estimated cardiovascular patient populations for each market using WHO data, local epidemiological surveys, and treatment rate assumptions
Regulatory pathway mapping: Analyzed drug approval requirements, timelines, and local clinical trial requirements for each country
Pricing and affordability analysis: Assessed pricing environments, reference pricing systems, government procurement processes, and affordability thresholds
Partnership landscape mapping: Identified and profiled 40+ potential local partners (distributors, licensees, JV candidates) with due diligence
Competitive analysis: Mapped current cardiovascular drug availability, generic penetration, and local manufacturer presence in each market
Investment modeling: Built market-specific investment projections including registration costs, partnership economics, and launch investment
We recommended a phased entry strategy: Phase 1 (immediate) — enter 3 high-attractiveness markets (India, Brazil, Mexico) through licensing partnerships with established local distributors. Phase 2 (Year 2) — enter 2 markets (Indonesia, Vietnam) through joint ventures. Phase 3 (Year 3-4) — evaluate 3 markets (Philippines, Thailand, Argentina) based on Phase 1 performance. We identified 15 partnership candidates with detailed due diligence and recommended 3 specific partners for Phase 1 markets.
Phase 1 (Weeks 1-4): Market attractiveness analysis and patient population sizing for 8 emerging markets
Phase 2 (Weeks 3-7): Regulatory pathway mapping and pricing/affordability analysis
Phase 3 (Weeks 6-10): Partnership landscape mapping with 40+ candidate profiles
Phase 4 (Weeks 9-13): Competitive analysis and investment modeling
Phase 5 (Weeks 13-16): Phased entry roadmap with partner recommendations and investment projections
| Metric | Before | After | Impact |
|---|---|---|---|
| Emerging Market Revenue | 8% of total | 25% target (5-year) | On track to achieve board target through phased entry |
| Market Entry Cost | Unbudgeted | $28M (3 markets, Phase 1) | 30% lower than initial internal estimates through partner selection |
| Partnership Quality | 2 failed attempts | 3 vetted partners selected | Due diligence process prevented repeat of previous failures |
| Regulatory Timeline | Unknown | 12-18 months per market | Clear registration pathway with local regulatory expertise |
| Pricing Strategy | No local pricing data | Market-specific pricing with reference analysis | Avoided underpricing in Brazil and overpricing in India |
“We had failed twice trying to enter emerging markets on our own. Medifirm's systematic approach — from market scoring to partner due diligence to pricing strategy — gave us the confidence and the framework to succeed. We're now live in India and Brazil with the right partners at the right price points.”
VP, Emerging Markets
Anonymous Client J
Forecast
Phased entry into 8 emerging markets projected to generate $340M cumulative revenue over 5 years, representing 12% of global portfolio revenue.
Every engagement starts with understanding your unique strategic challenge. Partner with Medifirm to transform data into decisions.